JP2022544380A5 - - Google Patents

Info

Publication number
JP2022544380A5
JP2022544380A5 JP2022508590A JP2022508590A JP2022544380A5 JP 2022544380 A5 JP2022544380 A5 JP 2022544380A5 JP 2022508590 A JP2022508590 A JP 2022508590A JP 2022508590 A JP2022508590 A JP 2022508590A JP 2022544380 A5 JP2022544380 A5 JP 2022544380A5
Authority
JP
Japan
Prior art keywords
inventions described
inventions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022508590A
Other languages
English (en)
Japanese (ja)
Other versions
JP7846613B2 (ja
JP2022544380A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045442 external-priority patent/WO2021030198A1/en
Publication of JP2022544380A publication Critical patent/JP2022544380A/ja
Publication of JP2022544380A5 publication Critical patent/JP2022544380A5/ja
Application granted granted Critical
Publication of JP7846613B2 publication Critical patent/JP7846613B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022508590A 2019-08-09 2020-08-07 病原菌を抑制するための組成物及び方法 Active JP7846613B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962884917P 2019-08-09 2019-08-09
US62/884,917 2019-08-09
US201962901206P 2019-09-16 2019-09-16
US62/901,206 2019-09-16
US201962947517P 2019-12-12 2019-12-12
US62/947,517 2019-12-12
US202063031299P 2020-05-28 2020-05-28
US63/031,299 2020-05-28
PCT/US2020/045442 WO2021030198A1 (en) 2019-08-09 2020-08-07 Compositions and methods for suppressing pathogenic organisms

Publications (3)

Publication Number Publication Date
JP2022544380A JP2022544380A (ja) 2022-10-18
JP2022544380A5 true JP2022544380A5 (https=) 2023-08-17
JP7846613B2 JP7846613B2 (ja) 2026-04-15

Family

ID=74571198

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022508590A Active JP7846613B2 (ja) 2019-08-09 2020-08-07 病原菌を抑制するための組成物及び方法

Country Status (5)

Country Link
US (1) US20220409674A1 (https=)
EP (1) EP4010013A4 (https=)
JP (1) JP7846613B2 (https=)
CN (1) CN114502183A (https=)
WO (1) WO2021030198A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3706767A4 (en) * 2017-11-09 2021-12-15 Vedanta Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
GB202217266D0 (en) * 2022-11-18 2023-01-04 Imperial College Innovations Ltd Anti-biotic-resistant bacteria
EP4687930A2 (en) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Use of designed bacterial compositions for infection treatment
EP4687931A1 (en) * 2023-04-04 2026-02-11 Vedanta Biosciences, Inc. Compositions and methods for treating or preventing clostridium difficile infection, neutropenia, cardiovascular disease, asthma, and/or cancer
WO2025166242A1 (en) * 2024-02-01 2025-08-07 Vedanta Biosciences, Inc. Compositions and methods for decreasing dysbiosis and/or preventing inflammatory bowel disease
EP4663196A1 (en) 2024-06-13 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Decolonization of pathogenic enterobacteria, such as e. coli and/or klebsiella pneumoniae, from the gut using strains of e. coli

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2007075186A2 (en) * 2005-04-18 2007-07-05 The Regents Of The University Of California Antimicrobial therapy for bacterial infections
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) * 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
EP2994758B1 (en) * 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180000872A1 (en) * 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
AU2017318650B2 (en) * 2016-09-02 2021-12-09 Société des Produits Nestlé S.A. Compositions and methods for modulating gastrointestinal microflora in a canine
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
AU2018302641B2 (en) * 2017-07-18 2024-12-19 Keio University Anti-bacterial composition against Th1 cell-inducing bacteria
EP3723776A4 (en) * 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
CN117202919A (zh) * 2021-02-18 2023-12-08 韦丹塔生物科学股份有限公司 用于抑制病原生物体的组合物和方法

Similar Documents

Publication Publication Date Title
JP2021151238A5 (https=)
JP2023085489A5 (https=)
JP2022028828A5 (https=)
JP2022025124A5 (https=)
JP2023105131A5 (https=)
JP2022068302A5 (https=)
JP2021185136A5 (https=)
JP2020007340A5 (https=)
JP2023022224A5 (https=)
JP2021038271A5 (https=)
JP2023052878A5 (https=)
JP2020042034A5 (https=)
JP2021100406A5 (https=)
JP2025506484A5 (https=)
JP2022544380A5 (https=)
JP2022537813A5 (https=)
JP2021524864A5 (https=)
JP2021129286A5 (https=)
JP2020171301A5 (https=)
JP2020120660A5 (https=)
JP2024507827A5 (https=)
JP2022022379A5 (https=)
JP2024534771A5 (https=)
JP2020141705A5 (https=)
JP2023182736A5 (https=)